This is a routine leadership formalization — the interim CEO was made permanent with a standard compensation package. No financial data or guidance was released. Monitor the Q1 2026 earnings call on May 14, 2026 for actual performance metrics and any forward guidance.
Price Chart
Executive Summary
AVITA Medical appointed Cary Vance as permanent President and CEO, formalizing his role after serving as Interim CEO since October 2025, and appointed Jan Stern Reed as Board Chair. The filing includes a new employment agreement with a $702,000 base salary, 80% target bonus, and equity grants totaling ~$3.35M subject to stockholder approval. This is a routine leadership formalization with no material financial data or guidance provided.
Key Facts
- Cary Vance appointed President and CEO effective April 30, 2026, after serving as Interim CEO since October 2025
- Jan Stern Reed appointed Chair of the Board, replacing the Lead Independent Director role
- Employment agreement provides $702,000 annual base salary with 80% target bonus
- Equity grants of ~$2.53M (50% RSUs/50% options) and ~$825K (100% RSUs) subject to stockholder approval at 2027 annual meeting
- Severance includes 18 months base salary and COBRA reimbursement for termination without cause or for good reason
- No financial results, guidance, or preliminary earnings disclosed in this filing
Financial Impact
CEO compensation package with $702K base salary, 80% bonus target, and ~$3.35M in equity grants subject to stockholder approval
Risk Factors
- Equity grants require stockholder approval at 2027 annual meeting — if not approved, retention risk increases
- No financial results or guidance provided — uncertainty about underlying business performance remains
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-201662 |
| Document: 0001193125-26-201662-index.html | 0001193125-26-201662 |
| Document: 0001193125-26-201662.txt | 0001193125-26-201662 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers